What is the oral dose of Cardizem (diltiazem) for atrial fibrillation (AFib)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Oral Diltiazem Dosing for Atrial Fibrillation

For atrial fibrillation rate control, the recommended oral diltiazem dosage is 120-360 mg daily in divided doses, with extended-release formulations available for once-daily dosing. 1

Dosing Guidelines

Initial Dosing

  • Standard starting dose: 120 mg daily, divided into multiple doses
  • Extended-release formulations: Can be given as a single daily dose
  • Titration: Increase gradually based on heart rate response

Maintenance Dosing

  • Typical maintenance range: 120-360 mg daily 1
  • Extended-release formulations:
    • Once-daily dosing (improves adherence)
    • Provides more consistent plasma levels

Administration Considerations

Formulation Options

  • Immediate-release: Divided doses (usually 3-4 times daily)
  • Extended-release: Once-daily dosing
  • When transitioning from IV to oral therapy:
    • Median oral dose is approximately 300 mg/day 2
    • Start oral therapy 4 hours before discontinuing IV infusion

Monitoring Parameters

  • Heart rate: Goal is generally 60-80 bpm at rest and 90-115 bpm during moderate exercise 1
  • Blood pressure: Monitor for hypotension
  • Symptoms: Assess for improvement in AF-related symptoms
  • ECG: Evaluate for heart block or bradycardia

Special Considerations

Efficacy

  • Diltiazem is a Class I recommendation (Level of Evidence B) for rate control in AF 1
  • Studies show that medium-dose diltiazem (240 mg/day) combined with digoxin provides effective rate control both at rest and during exercise 3
  • Higher doses (≥0.13 mg/kg equivalent) achieve faster heart rate control than lower doses 4

Safety Concerns

  • Major side effects: Hypotension, heart block, heart failure 1
  • Contraindications:
    • AV block greater than first degree (without pacemaker)
    • Sick sinus syndrome (without pacemaker)
    • Decompensated heart failure/severe LV dysfunction
    • Wolff-Parkinson-White syndrome with AF/atrial flutter
    • Hypotension

Drug Interactions

  • Diltiazem is a substrate of CYP3A4 and a moderate CYP3A4 inhibitor
  • Significant interactions with: apixaban, itraconazole, bosutinib, ceritinib, cilostazol, cyclosporine, everolimus, ibrutinib, idelalisib, ivabradine, lomitapide, olaparib, ranolazine, rifampin, simeprevir 1

Alternative Rate Control Options

If diltiazem is ineffective or contraindicated, consider:

  • Beta-blockers (metoprolol, propranolol)
  • Verapamil
  • Digoxin (particularly in heart failure patients)
  • Amiodarone (when other measures are unsuccessful)

Clinical Pearls

  • Heart rate control is generally considered adequate when ventricular response is 60-80 bpm at rest and 90-115 bpm during moderate exercise 1
  • Combination therapy with digoxin may enhance rate control and allow for lower diltiazem doses 3
  • Medium-dose diltiazem (240 mg/day) with digoxin provides effective and safe rate control with fewer side effects than high-dose diltiazem alone 3
  • Extended-release formulations improve adherence and provide more consistent plasma levels throughout the day

Remember that the primary goal of rate control is to improve symptoms and quality of life while preventing tachycardia-induced cardiomyopathy, rather than achieving a specific heart rate target.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.